Month: April 2012

Diabetes treatment plans and goals should be tailored to each person, new guidelines for doctors say. The American Diabetes Association released the guidelines. They were developed jointly with the European Association for the Study of Diabetes. The guidelines say the best care plan for each person depends on several things. These include age, other health conditions, finances and motivation. For example, the blood sugar goal for a younger, mostly healthy person might be near normal. But this might not be the best goal for someone older with multiple health problems. For some people, aiming for near-normal blood sugar levels can lead to many episodes of hypoglycemia (very low blood sugar). This can be risky, especially for older adults. Some may be safer if they aim for slightly higher blood sugar levels. Having other conditions increases the number of drugs people take.

Keep moving to keep your brain in good shape, a new study suggests. The research focused on a group of 716 adults without dementia. Their average age was 82. They wore a device called an actigraph on one wrist for 10 days. This device keeps track of everyday movements as well as structured exercise. People in the study also took tests to measure their memory and thinking skills. These were repeated every year for 4 years. During the 4 years, 71 people developed signs of Alzheimer’s disease. Those who were least active at the start of the study were twice as likely to develop Alzheimer’s as those who were most active. People with the least intense activity were almost 3 times as likely to develop Alzheimer’s as those with the most intense activity. Overall, most movement came from everyday activities such housecleaning, cooking or gardening, not structured exercise.

Two types of drugs can help to reduce the risk that early kidney disease will get much worse, a new study finds. Researchers put together the results of 110 previous studies. In those studies, people with early kidney disease were treated with drugs that lower blood pressure. They were compared with people who got placebo (fake) pills. Some of the drugs used were angiotensin-converting enzyme (ACE) inhibitors. These include captopril (Capoten), enalapril (Vasotec) and others. People who received ACE inhibitors were 35% less likely to develop end-stage renal (kidney) disease. Angiotensin-receptor blockers (ARBs) reduced risk by 23%. ARBs include candesartan (Atacand), valsartan (Diovan) and others. People with early kidney disease that had signs of getting worse received the greatest benefit from both types of drugs.